Treatment with azacitidine (AZA) has been suggested to be of benefit for higher-risk myelodysplastic syndrome (HR-MDS) patients with chromosome 7 abnormalities (Abn 7). This retrospective study of 235 HR-MDS patients with Abn 7 treated with AZA (n = 115) versus best supportive care (BSC; n = 120), assessed AZA treatment as a time-varying variable in multivariable analysis. A Cox Regression model with time-interaction terms of overall survival (OS) at different time points confirmed that, while chromosome 7 cytogenetic categories (complex karyotype [CK] versus non-CK) and International Prognostic Scoring System risk (high versus intermediate-2) retained poor prognosis over time, AZA treatment had a favourable impact on OS during the first 3 years of treatment compared to BSC (Hazard ratio [HR] 0Á5 P < 0Á001 at 1 year, 0Á7 P = 0Á019 at 2 years; 0Á73 P = 0Á029 at 3 years). This benefit was present in all chromosome 7 categories, but tended to be greater in patients with CK (risk reduction of 82%, 68% and 53% at 1, 3 and 6 months in CK patients; 79% at 1 month in non-CK patients, P < 0Á05 for all). AZA also significantly improved progression-free survival (P < 0Á01). This study confirms a time-dependent benefit of AZA on outcome in patients with HR-MDS and cytogenetic abnormalities involving chromosome 7, especially for those with CK.
Summary
Treatment with azacitidine (AZA) has been suggested to be of benefit for higher-risk myelodysplastic syndrome (HR-MDS) patients with chromosome 7 abnormalities (Abn 7). This retrospective study of 235 HR-MDS patients with Abn 7 treated with AZA (n = 115) versus best supportive care (BSC; n = 120), assessed AZA treatment as a time-varying variable in multivariable analysis. A Cox Regression model with time-interaction terms of overall survival (OS) at different time points confirmed that, while chromosome 7 cytogenetic categories (complex karyotype [CK] versus non-CK) and International Prognostic Scoring System risk (high versus intermediate-2) retained poor prognosis over time, AZA treatment had a favourable impact on OS during the first 3 years of treatment compared to BSC (Hazard ratio [HR] 0Á5 P < 0Á001 at 1 year, 0Á7 P = 0Á019 at 2 years; 0Á73 P = 0Á029 at 3 years). This benefit was present in all chromosome 7 categories, but tended to be greater in patients with CK (risk reduction of 82%, 68% and 53% at 1, 3 and 6 months in CK patients; 79% at 1 month in non-CK patients, P < 0Á05 for all). AZA also significantly improved progression-free survival (P < 0Á01). This study confirms a time-dependent benefit of AZA on outcome in patients with HR-MDS and cytogenetic abnormalities involving chromosome 7, especially for those with CK.
Myelodysplastic syndromes (MDS) are clonal haematopoietic stem cell disorders characterized by morphological dysplasia in the bone marrow, peripheral cytopenia and an increased risk of evolution into acute myeloid leukaemia (AML). Although the only curative approach for these patients is allogeneic haematopoietic stem cell transplantation (HSCT) (Santini et al, 2010; Greenberg et al, 2011) , hypomethylating agents have recently been shown to modify the disease course Stone, 2009) .
Prognostication of patients with MDS has been largely based on cytogenetic features, first in the International Prognostic Scoring System (IPSS) score (Greenberg et al, 1997) , which distinguished three cytogenetic risk categories, in which chromosome 7 abnormalities (Abn 7) were included in the high-risk category. More recently, in the revised IPSS classification (IPSS-R), data from larger series allowed better cytogenetic stratification, considering 17 specific chromosomal abnormalities classified in five cytogenetic categories with clear prognostic impact (Sole et al, 2005; Greenberg et al, 2012; Schanz et al, 2012) . In particular, this large series confirmed previous findings from the Spanish Grupo Español de S ındromes Mielodispl asicos (GESMD) cooperative group showing that patients with isolated monosomy 7 or isolated del(7q) have different prognosis (Cordoba et al, 2012) .
Several relatively small reports have suggested that MDS carrying Abn 7, mainly isolated monosomy 7, may specifically benefit from treatment with azacitidine (AZA) Ravandi et al, 2009) . This is particularly relevant due to the poor outcome of these patients with conventional chemotherapy Ravandi et al, 2009; (Knipp et al, 2007) however; those results not confirmed, especially for patients with complex karyotypes (Itzykson et al, 2011) .
In the current study, we analysed the impact of treatment with AZA on outcomes [response rate, overall survival (OS) and progression-free survival (PFS)] in a large series of higher-risk MDS patients with Abn 7 receiving AZA or best supportive care (BSC).
Patients and methods

Inclusion criteria
Inclusion criteria in this retrospective study were: (i) higherrisk MDS, according to the World Health Organization [WHO] 2008 criteria) (Swerdlow et al, 2008) with high or intermediate 2 (int-2) IPSS risk (Greenberg et al, 1997) , (ii) prospectively enrolled in the French and Spanish MDS registries (between 2005 and and with complete follow-up data available (iii) presence of an Abn 7 (with or without other chromosomal abnormalities). Patients who received intensive AML-type chemotherapy or allogeneic HSCT were excluded from this analysis. Eligible patients were further stratified into four subgroups according to the cytogenetic Aza in HR-MDS Chr7 Abnormalities, GESMD and GFM Data ª 2018 John Wiley & Sons Ltd abnormalities present: (i) monosomy 7, isolated or with another single abnormality (non-complex -7), (ii) del(7q), isolated or with another single abnormality (non-complex del(7q), (iii) 7p-isolated or with another single abnormality (non-complex 7p-), and (iv) complex karyotype (CK) i.e. at least 3 cytogenetic abnormalities including any Abn 7. Two groups were established for each cytogenetic category according to the treatment approach received: (i) The AZA group (defined as patients who received at least one cycle of AZA in a clinical trial, compassionate use programme or following European Medicines Agency approval for higher-risk MDS) and (ii) The supportive care group (BSC, patients receiving only transfusions and antibiotics). Treatment decision (AZA or BSC) was made by the treating physician and was based on his judgment and drug availability at the time of treatment. Response to treatment was evaluated after 4-6 cycles of AZA and response was defined according to the International Working Group criteria 2006 for MDS (Cheson et al, 2006) : complete remission (CR), partial remission (PR), stable disease with haematological improvement (HI), stable disease without haematological improvement (SD) and progressive disease (PD). Red blood cell (RBC) transfusion independence, defined as 8 weeks or more without RBC transfusions, was also evaluated.
The different survival outcomes were defined as time from diagnosis of higher risk MDS (diagnosis) to the corresponding event: death for OS, death or PD (blast increase) for PFS.
Patients were included after informed consent in accordance with the Declaration of Helsinki. The institutional review board of the GESMD and Groupe Francophone des My elodysplasies (GFM) approved the study.
Statistical Methods
The statistical analysis was performed using R v3.1.2 (Simon & Makuch, 1984; Luis Meira-Machado, 2011; R Development Core Team 2011; Therneau, 2014) . For all statistical tests a nominal significance level of 5% (P < 0Á05) was applied. No adjustment for multiple tests was performed. All data spreadsheets, analysis codes and outputs were electronically stored and archived.
The relationship between OS and potential explanatory variables (age, karyotype, IPSS, WHO, de novo MDS and treatment) was examined by means of bivariate analyses. Survival functions for each explanatory variable and each group were obtained using the Kaplan-Meier estimator. A collinearity study excluded significant associations between treatment and potential risk factors including age, gender, karyotype, IPSS, WHO, karyotype and counts.
To apply a multivariate Cox proportional hazards regression model, the hypothesis of proportional risks was evaluated inspecting the risk functions Schoenfeld residuals. The hypothesis of proportional risks between the patients treated with AZA and BSC was rejected. Thus, the effect of AZA treatment on OS had a time varying pattern, with a positive early effect that was reduced with longer follow-up. To circumvent this methodological limitation of standard Cox models, multivariate analysis of OS was performed including interaction terms between treatment and time. In order to explore and represent the relationship between time and risk, the Aalen's nonparametric estimator was also used and, to quantify the AZA treatment's time-varying effects, a Cox model including relevant explanatory variables and time interaction terms was used. This model allowed estimating the benefit of AZA over BSC at different time points (full information in Appendix S1, Figures S1-S4). The potential interaction between AZA treatment and karyotype was also explored. The same methodological approach was followed for the secondary outcome variable, PFS.
Results
Baseline patient characteristics
Main baseline characteristics for the patients are shown in Table I . Two hundred and thirty-five patients with Abn 7 were analysed, including 115 treated with AZA and 120 patients who received BSC (the control group).
Seventy-four (64%) of AZA patients had de novo MDS and 41 (36%) had therapy-related (secondary MDS), compared to 70 (90%) and 8 patients (10%) in the BSC group (P = 0Á0001). According to WHO 2008 classification (Swerdlow et al, 2008) , 65% in the AZA group and 48% in the BSC group had refractory anaemia with excess of blasts type 2 (RAEB-2) or secondary AML (AML with <30% of blasts) (P = 0Á015). The AZA and BSC groups were well balanced for other baseline parameters, including age, gender, cytogenetic risk category and IPSS risk. In the AZA group, 55% of the patients were IPSS high-risk and 45% int-2-risk and 61% had CK, 23% non-complex -7, 14% non-complex del(7q), and only 2 patients (1Á8%) had noncomplex 7p-. Median follow-up time from diagnosis was 47Á5 months (95% confidence interval [CI]: 24Á2-122Á9) in the AZA group and 59Á8 months (95% CI: 15Á5-not reached) in the BSC group (P = not significant [ns]). Median time from diagnosis to AZA treatment was 2 months (range 0-66Á2) ( Table I) .
Ninety-two patients (80%) received AZA according to the conventional 7 days every 28 days schedule whereas 20% received 5-day cycles. The median number of AZA cycles received was 5 (range, 1-32). Information on transfusion support at AZA onset was available in only 100 of 115 patients in the AZA group; 74% were RBC (57%) and/or platelet (18%) transfusion dependent (TD).
Outcome with AZA treatment
Twelve AZA patients were not evaluable for response according to IWG 2006 criteria because insufficient data was recovered. In the 103 patients evaluable for response to AZA, the overall response rate (ORR) was 37Á9% (39/103), including 14Á6% CR and 23Á3% SD with HI. Among AZA non-responders (62Á1%), 27Á1% had SD without HI, 23Á3% PD, and 11Á7% (n = 12) had early death (8, infection; 1, bleeding, 3, unknown cause). Eleven of 67 RBC-TD patients (16%) became RBC transfusion independent. Regarding the cytogenetics, the ORR was 38Á1% in patients with CK, 32% in patients with non-complex -7 and 46Á2% in patients with non-complex del(7q) (P = ns for complex versus non-complex, chi-square test, Fig 1) . Median response duration was 13Á1 months (95% CI 8Á8-16Á4) and duration of response was significantly higher for non-CK patients as compared to CK patients [15Á7 months (95% CI 12Á2-18Á2) vs. 9Á4 months (95% CI 8Á2-10Á8), P = 0Á0022].
Interestingly, ORR was 37Á5% in "de novo" and 38Á4% in secondary MDS, respectively (P = ns).
Comparison between AZA treatment and BSC Overall survival. Median OS was not statistically significantly different between the 3 categories: median OS 11Á4 months for CK, 17Á8 for non-complex -7 and 21Á3 months for non-complex del(7q) patients, (P = 0Á1 and P = 0Á07; Fig 2) . This result suggests a specific improved outcome, especially for patients with CK receiving AZA (median OS of CK patients treated with BSC was 5Á5 months). No OS differences were also detected when comparing patients with de novo versus secondary MDS (14Á6 vs. 11Á1 months, for de novo versus secondary MDS, respectively, P = 0Á17). In univariate analysis, AZA treatment gave a borderline survival advantage over BSC by Kaplan-Meier estimators of the survival curves, with a median of 14 vs. 8Á5 months (log-rank test P = 0Á063). Fig 2. OS with azacitidine treatment compared with BSC. When comparing each group of treatments independently, it was confirmed that CK patients treated with BSC had a significantly lower OS (me OS 5Á5 of months) than those with -7 (13Á6 months, P = 0Á0054) and in del(7q) (19 months, P < 0Á001). Nevertheless, median OS in the AZA-treated group was not statistically significantly different between the 3 subsets [median OS 11Á4 months for CK versus 17Á8 and 21Á3 months for -7 and del(7q) patients, respectively (P = 0Á1 and P = 0Á07). This suggests a specific improved outcome, particularly for patients with CK receiving AZA. AZA, azacitidine; BSC, best supportive care; CK, complex karyotype; OS, overall survival.
The OS benefit with AZA was more pronounced during the first months of treatment and decreased over time (Fig 3A) , with HRs of 0Á1, 0Á3, 0Á5 and 0Á8 at 1, 3, 6 and 12 months after treatment onset (P < 0Á0001 for the first 6 months and P = 0Á1 at 12 months). AZA improved OS in all chromosome 7 categories, 50% of risk reduction among CK patients, 45% among non-complex -7 and 30% among non-complex del(7q) at 6 months after treatment. Nevertheless, we observed a trend towards a greater risk benefit among CK patients (with the lowest HR and where differences between AZA and BSC retained statistical significance after 1 year after treatment) as compared to non-CK (with slightly higher HR and significant difference only during the first 6 months after treatment onset, Fig 3B) .
Multivariable analysis of OS at different time points is detailed in Tables II and III . AZA treatment had a significantly favourable impact on OS during the first 3 years of treatment as compared to BSC, confirming the trend observed in univariable analysis. This benefit was confirmed for the 3 cytogenetic categories with no differences between them (P = 0Á925). Nevertheless, the benefit of AZA treatment, compared to BSC, decreased over time, with an increase in HR from 0Á3 at 6 months, 0Á5 at 1 year and 0Á7 at 2 and 3 years.
PFS. Univariate analysis demonstrated significantly better PFS in the AZA group compared to BSC ( Figure S5 ). Multivariate analysis confirmed an increase in PFS among patients receiving AZA (Table IV) and again it was noted when timeinteraction terms were included in the final model: treatment with AZA significantly decreased the risk of death or progression (HR 0Á01, P < 0Á01). As for OS analysis, the benefit of AZA treatment decreased after the first year of treatment, from a HR of 0Á4 (P < 0Á001) and 0Á6 (P = 0Á004) at 6 and 12 months, to a HR of 0Á79 (P = 0Á107) at 24 months, respectively (Table IV and Table SI ). The benefit of AZA treatment in terms of PFS was similar in the 3 cytogenetic categories (P = 0Á794).
Discussion
In this large retrospective cohort of higher-risk MDS patients with Abn 7, we demonstrated a clear advantage in OS and PFS for patients treated with AZA compared with those receiving BSC, especially in patients with CK.
Information suggesting a particular efficacy of AZA in patients with Abn 7 was based on low patient numbers Itzykson et al, 2011; Komrokji et al, 2013) . Additionally, apart from the AZA-001 trial , there are no data comparing long-term outcomes after AZA and BSC. In the AZA-001 randomized clinical trial, AZA showed an OS benefit over conventional care in higherrisk MDS patients with Abn 7 , but only 30 patients in this category had received AZA. Several studies demonstrated that chemotherapy not a reliable option for patients with higher-risk MDS and AML with CK because of the lower complete response rates (46% as compared to 70% for those with no CK) and the poorer OS (median of 4 months as compared to 18 months for those with normal karyotype) Knipp et al, 2007) . In the AZA-001 trial, only 25 patients were candidates for induction and no significant differences were observed due to the low number of patients included, and is why the present study focused on BSC patients. On average, our patients had higher risk features than previous series of higher-risk MDS patients: Cytogenetic were poor-risk in all cases [compared with 47% and 28% in the GFM study (Itzykson et al, 2011) and AZA-001 trial , respectively] and 36% of our patients had secondary MDS (versus 26% and 0% in the GFM study and AZA-001 trial). In addition, 65% of the patients in our AZA group had >10% bone marrow blasts versus 48% of the BSC group and 36% had secondary MDS (versus 10% in the BSC group). With those poor risk factors, the ORR in our series (37Á8%) was somewhat lower than in the GFM retrospective study (Itzykson et al, 2011 ) (43%) and the prospective AZA-001 clinical trial (49%) (Fenaux & Ades, 2009; while OS was only slightly shorter in our cohort (median, 14 months for AZA recipients) than in other unselected series of higher risk MDS patients (median, 13-24 months) (Fenaux & Ades, 2009; Itzykson et al, 2011; Bernal et al, 2015; Dinmohamed et al, 2015) . Thirty six percent of our patient population had secondary MDS, but their ORR was similar to that of de novo ORR (38Á5% and 37Á5%, P = ns, respectively), in agreement with previously published data (Muller-Thomas et al, 2014) . Thus, it appears that the effectiveness of AZA regarding the response rate in secondary MDS with Abn 7 is comparable to that seen in de novo MDS with these chromosomal abnormalities.
We found no clear differences in ORR in AZA treatment between the three different categories defined in this report (non-complex -7, non-complex del 7q and CK involving chromosome 7), although there was a trend towards better response in non-complex del(7q) patients (46Á1% ORR). This absence of clear differences in ORR between patients with non-complex and CK had been previously reported (Itzykson et al, 2011) . For OS, a trend towards better outcome was seen in del(7q) patients (median OS of 19 months vs. 13Á6 for -7 and 11Á4 months for CK, respectively). Of note, median OS was 13Á1 and 13Á3 months in patients with -7/del(7q) in AZA-treated patients, respectively, in the AZA-001 clinical trial and GESMD retrospective studies (Fenaux & Ades, 2009 ). It is difficult to differentiate response and survival among patients with CK not involving Abn 7 because only a small number of patients with CK had no involvement of Chr 7. The conclusion of the recently published larger study that analysed karyotype and AZA treatment confirmed our results: baseline cytogenetic findings poorly predicted response to AZA but were strong predictors for OS (Sebert et al, 2017) . In the GFM study, patients with CK showed shorter response duration than non-CK patients (Itzykson et al, 2011) . Our study also confirmed shorter response duration in those patient subsets compared to non-CK patients (9Á4 vs. 15Á7 months, respectively) .
In the present series of MDS with chromosome 7 rearrangements, AZA improved OS compared to BSC. However, the improvement was only borderline in the univariate analysis, except in the first months of treatment. Multivariate analysis using time interaction effects better demonstrated this OS advantage, which however decreased during the second and third year of treatment, with a reduction in the risk of death of 70% in the first 6 months, 50% at 1 year and 30% at 2 and 3 years compared to BSC. This feature probably reflects the fact that responses induced by AZA are generally transient, with most patients losing their response after 6 months to 2 years, and confirming that AZA is not a curative approach.
We also analysed the interaction between karyotype and treatment and found no effect over the risk's function, meaning that efficacy was similar in all subtypes. Nevertheless, a trend towards a larger benefit of AZA treatment over BSC during the first year was observed for CK, compared to non-CK patients. AZA-treated CK patients had a lower HR and more durable impact on OS compared to non-CK patients (risk reduction of 82%, 68% and 53% at 1, 3 and 6 months in CK patients). Finally, PFS differences between AZA and BSC were similar to those found for OS, with a benefit over BSC during the first year that diminished with longer follow-up.
In the AZA-001 randomized clinical trial , the benefit of AZA over conventional care treatment (including BSC) in patients with Abn 7 was only seen when the karyotype was not complex (median OS of 24Á5 vs. 8Á1 for AZA versus conventional care treatment patients, respectively) while in CK patients the median OS was 5Á3 vs. 3Á9 months for AZA versus conventional care treatment patients). Our study, with a higher number of patients, demonstrated an OS benefit in patients with CK (median OS of 11Á4 months vs. 5Á5 months for BSC patients). A Dutch study (Dinmohamed et al, 2015) also found a global survival benefit with AZA treatment for patients with Abn 7 (median OS 21Á4 months with Aza vs. 3Á9 months for BSC; P = 0Á01).
To summarize, the current study shows a survival benefit of AZA treatment over BSC in higher-risk MDS patients with Abn 7, especially for those with CK. However, the survival improvement in survival remains modest. New treatment *P < 0Á05, **P < 0Á01. 
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